natgillin/translations-raw huggingface dataset:
R2b represents a hydrogen atom, a fluorine atom, a chlorine atom, methyl, ethyl, methoxy, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy; optionally wherein R2b represents a hydrogen atom, methyl, ethyl, methoxy, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoromethoxy or trifluoromethoxy; and R2c represents a hydrogen atom, a fluorine atom, a chlorine atom, methyl, monofluoromethyl, difluoromethyl or trifluoromethyl, or a prodrug thereof, or a pharmaceutically acceptable salt thereof. 
b predstavlja atom vodika, atom fluora, atom klora, metil, etil, metoksi, monofluorometil, difluorometil, trifluorometil, difluorometoksi ili trifluorometoksi; po izboru gdje R2b predstavlja atom vodika, metil, etil, metoksi, monofluorometil, difluorometil, trifluorometil, difluorometoksi ili trifluorometoksi; i c predstavlja atom vodika, atom fluora, atom klora, metil, monofluorometil, difluorometil ili trifluorometil, ili prolijek, ili farmaceutski prihvatljiva sol.
An indolizine derivative as claimed in claim 8, wherein R1a represents a hydroxy group, or a prodrug thereof, or a pharmaceutically acceptable salt thereof. 
Derivat indolizina prema zahtjevu 8, gdje R1a predstavlja hidroksi skupinu, ili prolijek, ili farmaceutski prihvatljiva sol.
An indolizine derivative as claimed in claim 8, which is selected from the group consisting of 4-(1-cyanoindolizine-3-yl) benzoic acid, 
Derivat indolizina prema zahtjevu 8, koji je izabran iz grupe koja obuhvaća: -(1-cijanoindolizin-3-il) benzojeva kiselina,
A pharmaceutical composition as claimed in claim 13, for use in the prevention or treatment of a disease selected from the group consisting of hyperuricemia, gouty tophus, gouty arthritis, renal disorder associated with hyperuricemia and urinary calculi optionally for use in the prevention or treatment of hyperuricemia, optionally for use in lowering serum uric acid level. 
Farmaceutska smjesa prema zahtjevu 13, za uporabu u prevenciji ili liječenju bolesti izabrane iz grupe koja obuhvaća hiperurikemiju, giht s kamencima, artritični giht, poremećaj bubrega povezan s hiperurikemijom i urinarni kamenci po izboru za uporabu u prevenciji ili liječenju hiperurikemije, po izboru za uporabu za snižavanje razine urične kiseline u serumu.
A pharmaceutical composition as claimed in claim 13, which is a uric acid production inhibitor. 
Farmaceutska smjesa prema zahtjevu 13, koja je inhibitor proizvodnje urične kiseline.
Use of a compound selected from the group consisting of Roflumilast, a pharmaceutically acceptable salt of Roflumilast, Roflumilast-N-Oxide and a pharmaceutically acceptable salt of Roflumilast-N-Oxide for the production of a pharmaceutical composition for the preventive treatment of pulmonary hypertension. 
Uporaba, naznačena time, da se spoj odabran iz skupine koja sadrži roflumilast, farmaceutski prihvatljivu sol od roflumilasta, roflumilast-N-oksid i farmaceutski prihvatljivu sol od roflumilast-N-oksida, upotrebljava za proizvodnju farmaceutskog sastava za preventivno liječenje pulmonalne hipertenzije.
Use according to any one of claims 6 or 7, wherein pulmonary hypertension stands for familiar pulmonary arterial hypertension. 
Uporaba prema jednom od zahtjeva 6 ili 7, naznačena time, da se pulmonalna hipertenzija odnosi na obiteljsku pulmonalnu arterijsku hipertenziju.
Use according to any one of claims 6 or 7, wherein pulmonary hypertension stands for pulmonary hypertension associated with thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloprotiferative disorders or splenectomy 
Uporaba prema jednom od zahtjeva 6 ili 7, naznačena time, da se pulmonalna hipertenzija odnosi na pulmonalnu arterijsku hipertenziju koja je povezana s tiroidnim poremećajima, poremećajem skladištenja glikogena, Gaucherovom bolešću, nasljednom hemoragijskom teleangiektazijom, hemoglobinopatijama, mijeloproliferativnim poremećajima ili splenektomijom.
with the proviso that the compound of formula (I) is not: 
uz uvjet da spoj formule (I) nije:
A compound for use according to claim 7, wherein the cognitive or neurodegenerative disease or disorder is selected from a group consisting of a mood disorder, an anxiety, a schizophrenia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's chorea, amyotrophic lateral sclerosis, Creutzfeld-Jakob disease, a trauma-induced neurodegeneration, AIDS-induced encephalopathy, a non-AIDS-induced encephalopathy, Fragile X syndrome, an autism spectrum disorder, and a combination thereof. 
Spoj za uporabu prema zahtjevu 7, gdje se kognitivna ili neurodegenerativna bolest ili poremećaj izabire iz grupe koja obuhvaća poremećaj raspoloženja, anksioznost, shizofreniju, Alzheimerovu bolest, Parkinsonovu bolest, multiplu sklerozu, Huntingtonovu koreju, amiotrofnu lateralnu sklerozu, Creutzfeld-Jakobovu bolest, traumom induciranu neurodegeneracijun, AIDS-om induciranu encefalopatiju, ne-AIDS-om induciranu encefalopatiju, sindrom fragilnog X, poremećaj iz područja autizma i njihovu kombinaciju.
A compound for use according to claim 7, wherein the cognitive or neurodegenerative disease or disorder is Fragile X syndrome. 
Spoj za uporabu prema zahtjevu 7, gdje je kognitivna ili neurodegenerativna bolest ili poremećaj sindrom fragilnog X.
A compound for use according to claim 8, wherein the mood disorder is a depression. 
Spoj za uporabu prema zahtjevu 8, gdje je poremećaj raspoloženja depresija.
At least one compound of claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or disorder in the central nervous system, wherein the central nervous system disease or disorder is a pain disease or disorder selected from the group consisting of inflammatory pain, neuropathic pain and migraine pain. 
Barem jedan spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju bolesti ili poremećaja središnjeg živčanog sustava, gdje bolest ili poremećaj središnjeg živčanog sustava jest bolna bolest ili poremećaj izabran iz grupe koja obuhvaća upalnu bol, neuropatsku bol i migrenu.
A compound for use according to claim 7, wherein the disease or disorder is an anxiety. 
Spoj za uporabu prema zahtjevu 7, gdje je bolest ili poremećaj anksioznost.
A compound for use according to claim 7, wherein the disease or disorder is Parkinson's disease. 
Spoj za uporabu prema zahtjevu 7, gdje je bolest ili poremećaj Parkinsonova bolest.
The pharmaceutical composition according to claim 7, for use in treating and/or preventing pain. 
Farmaceutski pripravak prema zahtjevu 7, za uporabu u liječenju i/ili prevenciji boli.
The pharmaceutical composition according to claim 7, for use in treating and/or preventing pain caused by diabetic neuropathy. 
Farmaceutski pripravak prema zahtjevu 7, za uporabu u liječenju i/ili prevenciji boli koja je uzrokovana dijabetičkom neuropatijom.
The pharmaceutical composition according to claim 7, for use in treating and/or preventing postherpetic neuralgia. 
Farmaceutski pripravak prema zahtjevu 7, za uporabu u liječenju i/ili prevenciji neuralgije nakon herpesa.
where RD is independently selected from R, CO2R, COR, CHO, CO2H, and halo; CBA is a cell binding agent selected from an antibody and a fragment of an antibody that contains at least one binding site; 
je poveznica spojena na sredstvo za vezanje stanice odabrano od protutijela, fragmenta protutijela koji sadrži najmanje jedno vezno mjesto, te cikličkog polipeptida; Q je neovisno odabran između O, S i NH;
Compound for use according to Claim 3, or use according to Claim 4, wherein the infection is caused by a Gram-negative bacterium selected from Enterobactericeae, Bacteroidaceae, Vibrionaceae, Pasteurellae, Pseudomonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, any species of Proteeae, Acinetobacter spp ., Helicobacter spp ., and Campylobacter spp .. 
Spoj za uporabu prema patentnom zahtjevu 3, ili uporabu prema patentnom zahtjevu 4, naznačen time da je zaraza uzrokovana Gram-negativnom bakterijom izabranom od Enterobactericeae, Bacteroidaceae, Vibrionaceae, Pasteurellae, Pseudomonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, bilo koja vrsta Proteeae, Acinetobacter spp., Helicobacter spp., i Capylobacter spp.
A process for preparing a compound of Formula (I): 
Postupak dobivanja spoja Formule (I):
or a pharmaceutically acceptable free amine, salt, or stereoisomer thereof, comprising the step of cyclizing a compound of Formula (II) or (IIA): 
[image], ili njegove farmaceutski prihvatljive soli, solvata, polimorfa ili stereoizomera, naznačen time što se sastoji u koraku cikliziranja spoja Formule (II) ili (IIA):
A process for preparing a vaccine antigen in a culture of a Vero cell line, comprising a step of testing for a pathogen selected from the group consisting of canine parvovirus, JC polyomavirus, and circovirus. 
Postupak priprave antigena cjepiva u kulturi Vero stanične linije, koji sadrži korak testiranja na patogen izabran iz skupine koja sadrži parvovirus, JC poliomavirus i cirkovirus.
The process of claim 10, wherein the vaccine antigen is an attenuated influenza virus, a temperature-sensitive influenza virus or a cold-adapted influenza virus. 
Postupak prema patentnom zahtjevu 10, naznačen time da je antigen cjepiva oslabljeni virus influence, virus influence osjetljiv na temperaturu ili virus influence prilagođen na hladnoću.
is selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, alkoxyalkyl, each of these groups can be optionally substituted by one or more substituents selected from Y; 
je odabran od alkila, alkenila, alkinila, cikloalkila, cikloalkilalkila, heterocikloalkila, alkoksialkila, svaka od navedenih skupina može proizvoljno biti supstituirana sa jednim ili više supstituenata koji su odabrani od Y;
is selected from hydrogen, alkyl, cycloalkyl; 
je odabran od vodika, alkila, cikloalkila;
and R6 together can constitute a heterocycle; 
i R6 zajedno mogu tvoriti heterocikal;
and R3 can constitute a cycle which corresponds to the general formula (II), wherein: 
i R3 mogu tvoriti cikal koji odgovara općoj formuli (II), [image] pri čemu:
and A are defined as above; 
i A su definirani kao gore;
represents one or more substituents selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, wherein alkyl, cycloalkyl and aryl groups can be optionally substituted by one or more substituents, selected from hydroxy, halogen, alkyl, alkoxy, trifluoromethoxy, trifluoromethyl, alkylsulfonyl, NR7R8; R7 and R8 are independently selected from hydrogen, alkyl, cycloalkyl; 
predstavlja jedan ili više supstituenata odabranih od vodika, alkila, alkoksi, cikloalkila, arila, pri čemu alkilna, cikloalkilna i arilna skupina mogu biti proizvoljno supstituirane sa jednim ili više supstituenata, odabranih od hidroksi, halogena, alkila, alkoksi, trifluorometoksi, trifluorometila, alkilsulfonila, NR7R8; i R8 su neovisno odabrani od vodika, alkila, cikloalkila;
is selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl; each of these groups can be optionally substituted by one or more substituents selected from halogen, hydroxy; 
je odabran od alkila, cikloalkila, cikloalkilalkila, alkoksialkila; svaka od navedenih skupina može proizvoljno biti supstituirana sa jednim ili više supstituenata koji su odabrani od halogena i hidroksi;
A compound according to any of claims 1 to 2, wherein R1 is: ethyl, propyl, isopropyl, butyl; sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl. 
Spoj prema bilo kojem zahtjevu od 1 do 2, naznačen time da R1 je: etil, propil, izopropil, butil; sec-butil, tert-butil, ciklopropil, ciklopropilmetil.
A compound according to any of claims 1 to 6, wherein Y is: halogen, trifluoromethoxy, trifluoromethyl, carboxy, alkyl, alkoxy, alkylsulfonyl, two Y groups can form a methylenedioxy. 
Spoj prema bilo kojem zahtjevu od 1 do 6, naznačen time da Y je: halogen, trifluorometoksi, trifluorometil, karboksi, alkil, alkoksi, alkilsulfonil, dvije Y skupine mogu tvoriti metilendioksi.
reacting a compound of formula (1) with an amine R1-NH2, wherein R1 is as defined in claim 1, in the presence of a quaternary ammonium salt, such as aliquat 336, in an inert solvent, to give a compound of formula (2); 
reakciju spoja sa formulom (1) [image] sa aminom R1-NH2, pri čemu je R1 kako je definirano u zahtjevu 1, u prisutnosti kvaterne amonijeve soli, kao što je alikvot 336, u inertnom otapalu, da se dobije spoj sa formulom (2);
reacting a compound of formula (2) with a protected aminoacetaldehyde dialkylacetate, such as (2,2-dimethoxyethyl)amine, in an alcohol such as 2-propanol, to give a compound of formula (3); 
reakciju spoja sa formulom (2) sa zaštićenim aminoacetaldehid dialkilacetatom, kao što je (2,2-dimetoksietil)amin, u alkoholu kao što je 2-propanol, da se dobije spoj sa formulom (3);
cyclizating a compound of formula (3) under acidic conditions, in a solvent, such as acetic acid, and catalytic amount of concentrated hydrochloric acid, to give a compound of formula (4); 
ciklizacijom spoja sa formulom (3) u kiselim uvjetima, u otapalu, kao što je octena kiselina, te uz katalitičku količinu koncentrirane klorovodične kiseline, da se dobije spoj sa formulom (4);
reacting a compound of formula (5) with boronic acids or esters of boronic acids, wherein A is as defined in claim 1, in the presence of a base, such as sodium carbonate or potassium carbonate, and a catalyst, such as bis(triphenylphosphine) palladium(II)chloride, in an inert solvent, to give compounds of formula (I) as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts thereof. 
reakciju spoja sa formulom (5) sa boronskim kiselinama ili esterima boronskih kiselina, pri čemu A je kako je definirano u zahtjevu 1, u prisutnosti baze, kao što je natrijev karbonat ili kalijev karbonat, te katalizatorom, kao što je bis(trifenilfosfin) paladij(II)klorid, u inertnom otapalu, da se dobiju spojevi sa formulom (I) kao i njihovi oblici racemata, tautomeri, enantiomeri, diastereomeri, epimeri i polimorfi i njihove smjese, te njihove farmaceutski prihvatljive soli.
reacting a compound of formula (8) with an amine R1-NH2, wherein R1 is as defined in claim 1, in the presence of coupling agents, such as 1-hydroxybenzotriazole, benzotriazol-1-yl-oxytripyrrolidino phosphonium hexafluoro phosphate, carbonyldiimidazole or dicyclohexylcarbodiimide, or by in situ generation of mixed anhydride, by reaction e.g. 
reakciju spoja sa formulom (8) sa aminom R1-NH2, pri čemu R1 je kako je definirano u zahtjevu 1, u prisutnosti sredstava za spajanje, kao što je 1-hidroksibenzotriazol, benzotriazol-1-il-oksitripirolidino fosfonij heksafluoro fosfat, karbonildiimidazol ili dicikloheksilkarbodiimid, ili pomoću in situ stvaranja smjese anhidrida, uz reakciju npr.
deprotecting the amino function of compounds of formula (9), by using organic acid, such as trifluoroacetic acid, or mineral acid, such as hydrochloric acid, or by catalytic hydrogenation, in a solvent, to give a compound of formula (10); 
deprotekciju amino funkcije spojeva sa formulom (9), korištenjem organske kiseline, kao što je trifluorooctena kiselina, ili mineralne kiseline, kao što je klorovodična kiselina, ili sa katalitičkim hidrogeniranjem, u otapalu, da se dobije spoj sa formulom (10);
multiplexing the demapped cell words into Layer 1 signaling data; 
multipleksor konfiguriran za multipleksiranje konstelacijski mapiranih staničnih riječi u signalni podatak razine 1;
The crate of claim 1, wherein the stiffening portion (126a, 126c, 126d) is U-shaped and extends in a central area of the side wall (108a, 108b) toward the lower edge (124). 
Sanduk prema zahtjevu 1, naznačen time, da je element za ukrućenje (126a, 126c, 126d) u obliku slova U i proteže se u središnje područje bočne stijenke (108a, 108b) prema donjem rubu (124).
The crate of claims 1 or 2, wherein the stiffening portion (126a, 126c, 126d) extends towards the lower edge (124) such that a distance to the lower edge (124) is smaller than or equal to half the height of the side wall (108a, 108b). 
Sanduk prema zahtjevu 1 ili 2, naznačen time, da se element za ukrućenje (126a, 126c, 126d) proteže prema donjem rubu (124) tako da je udaljenost do donjeg ruba (124) manja ili je jednaka polovici visine bočne stijenke (108a, 108b).
The crate of one of claims 1 to 3, wherein the stiffening member (126) extends to the lower edge (124) of the side wall (108a, 108b). 
Sanduk prema jednom od zahtjeva 1 do 3, naznačen time, da se sredstvo za ukrućenje (126) proteže do donjeg ruba (124) bočne stijenke (108a, 108b).
The crate of one of claims 1 to 4, wherein the continuous stiffening member (126) comprises a plurality of stiffening portions extending towards the lower edge (124) of the side wall (108a, 108b). 
Sanduk prema jednom od zahtjeva 1 do 4, naznačen time, da neprekidno sredstvo za ukrućenje (126) obuhvaća veći broj elemenata za ukrućenje koji se protežu prema donjem rubu (124) bočne stijenke (108a, 108b).
The crate of claim 5, wherein the plurality of stiffening portions have the same or different distances to the lower edge (124) of the side wall (108a, 108b). 
Sanduk prema zahtjevu 5, naznačen time, da veći broj elemenata za ukrućenje imaju iste ili različite udaljenosti do donjeg ruba (124) bočne stijenke (108a, 108b).
The crate of claim 7, wherein the continuous stiffening member (126) is formed by water injection molding. 
Sanduk prema zahtjevu 7, naznačen time, da je neprekidno sredstvo za ukrućenje (126) oblikovano pomoću vodenog injektiranja u kalupu.
The crate of one of claims 1 to 9, wherein the crate is provided for receiving and/or transporting foods, for example fruits, vegetables, meat and the like. 
Sanduk prema jednom od zahtjeva 1 do 9, naznačen time, da je taj sanduk opremljen za držanje i/ili transport prehrambenih namirnica, primjerice voća, povrća, mesa i sličnog.
The compound according to claim 1, wherein R1 is an optionally substituted C1-6 alkyl, an optionally substituted 3- to 10-membered nonaromatic cyclic group or an optionally substituted 5- or 6-membered aromatic cyclic group. 
Spoj prema zahtjevu 1, naznačen time, da R1 je opcijski supstituiran C1-6alkil, opcijski supstituirana 3- do 10-člana nearomatska ciklička skupina ili opcijski supstituirana 5- do 6- člana aromatska ciklička skupina.
The compound according to claim 2, wherein R2 is an optionally substituted C1-6 alkyl. 
Spoj prema zahtjevu 2, naznačen time, da R2 je opcijski supstituiran C1-6alkil.
The compound according to claim 2, wherein W is an optionally substituted C1-4 alkylene. 
Spoj prema zahtjevu 2, naznačen time, da W je opcijski supstituiran C1-4alkilen.
The medicament according to claim 16 which is an agent for the prophylaxis or treatment of a circulatory disease. 
Lijek prema zahtjevu 16, naznačen time, da je on sredstvo za profilaksu ili liječenje cirkulacijske bolesti.
applying a bandpass filter to a second heart sound (S2) component to generate a filtered S2 component, the bandpass filter having a variable lower cutoff frequency that is initially greater than a maximum frequency of the S2 component; 
primjene pojasnog filtera na komponentu drugog srčanog zvuka (S2) kako bi se generirala filtrirana komponenta S2, te pojasni filter ima promjenjivu donju graničnu frekvenciju koja je inicijalno veća od najveće frekvencije komponente S2;
displaying the blood pressure estimate. 
prikazivanje procjene krvnog tlaka.
The method according to claim 1, wherein each of the S2 component and the filtered S2 component is represented by a respective amplitude value, and the amplitude value is calculated from at least one of a root-mean-square (rms) value, a peak value or a mean value of an absolute value. 
Postupak prema zahtjevu 1, naznačen time da su svaka S2 komponenta i filtrirana S2 komponenta prikazane sa odgovarajućom vrijednosti amplitude, te se vrijednost amplitude izračunava iz barem jedne vrijednosti odabrane od vrijednosti kvadratnog korijena srednjeg kvadrata (rms), vršne vrijednosti ili srednje vrijednosti apsolutne vrijednosti.
The method according to claim 4, 5, 6, 7, or 8, the extracting of the diastolic signal includes the steps of: synchronously receiving the PCG signal and an electrocardiogram (ECG) signal; and extracting the diastolic signal from the received PCG signal using the received ECG signal. 
Postupak prema zahtjevu 4, 5, 6, 7, ili 8, naznačen time da izdvajanje dijastoličkog signala sadrži korake: sinkroniziranog prijema PCG signala i signala elektrokardiograma (EKG); te izdvajanje dijastoličkog signala iz primljenog PCG signala korištenjem primljenog EKG signala.
The blood pressure analyzer according to claim 12, wherein the input port is further configured to receive an electrocardiogram (ECG) signal corresponding to the PCG signal, and wherein the diastolic signal extractor is configured to extract the diastolic signal using the corresponding ECG signal. 
Uređaj za analizu krvnog tlaka prema zahtjevu 12, naznačen time da je ulazni priključak nadalje podešen za primanje signala elektrokardiograma (EKG) koji odgovara signalu PCG, te pri čemu je uređaj za izdvajanje dijastoličkog signala podešen za izdvajanje dijastoličkog signala korištenjem odgovarajućeg EKG signala.
an anionic prepolymer A) containing from 5 to 25 meq/100 g dry matter of carboxylic groups prepared from: 
anionskog prepolimera A) koji sadrži od 5 do 25 meq/100 g suhe tvari karboksilnih skupina, kojeg se pripravlja s:
III) one or more anionic or potentially anionic polyols having two or more reactive groups toward the isocyanate group and at least one carboxylic or carboxylate group; 
III) jedim ili više anionskih ili potencijalno anionskih poliola s dvije ili više skupina koje reagiraju s izocijanatnom skupinom i najmanje jednom karboksilnom ili karboksilatnom skupinom;
Aqueous dispersion of any of claims from 1) to 3) in which the chain extender B) is in such an amount that at least 3% of free NCO groups in the prepolymer A) react with it. 
Vodena disperzija u skladu s bilo kojim od patentnih zahtjeva od 1) do 3), naznačena time što je produljivač lanca B) u takvoj količini da najmanje 3% slobodnih NCO skupina u prepolimeru A) reagira s njim.
Aqueous dispersion of claim 4) in which the nonionic polyols IV) are diols with a molecular weight below 150 or polyether polyols. 
Vodena disperzija u skladu s patentnim zahtjevom 4), naznačena time što su neionski polioli IV) dioli molekulske težine ispod 150 ili polieterski polioli.
Aqueous dispersion of claims 4) in which the polytetramethylene glycol represents in moles 100% of the molar sum of component II), IV) and V) of the prepolymer A). 
Vodena disperzija u skladu s patentnim zahtjevom 4), naznačena time što je politetrametilen-glikol molarno 100% od molarne sume komponenata II), IV) i V) prepolimera A).
a prepolymer A) is prepared containing from 5 for 25 meq/100 g of carboxylic groups reacting: 
prepolimer A) se pripravlja da sadrži od 5 do 25 meq/100 g karboksilnih skupina koje reagiraju s:
Method for the preparation of aqueous dispersions of any of claims from 10) to 12) in which in step iii) the chain extender B) is added in such an amount that between 3 and 50% of free NCO groups contained in the prepolymer A) react with it. 
Postupak priprave vodenih disperzija u skladu s bilo kojim od patentnih zahtjeva od 10) do 12), naznačen time što se u koraku iii) produljivač lanca B) dodaje u takvoj količini da između 3 i 50% slobodnih NCO skupina koje sadrži prepolimer A) reagira s njim.
Use of aqueous dispersions as described in claims from 1) to 9) for the coating of leather, fabrics, paper, cardboard, plastic, wood or metals with films of high opacity. 
Upotreba vodenih disperzija u skladu s patentnim zahtjevima od 1) do 9), naznačena time što su vodene disperzije namijenjene premazivanju kože, tkanine, papira, kartona, plastike, drva ili metala visoko neprozirnim filmovima.